symptoms (cough, wheeze, chest tightness, difficulty breathing, and/or sore throat), and facial swelling (eyelid, lip, tongue, and/or other facial swelling) within 2-24 h after influenza vaccination, with full resolution within 48 h after onset [1] [2] [3] [4] .
Across Canada, 1900 reports meeting this case definition were submitted in 2000-2001 via the passive adverse event surveillance system. Of these, 96% were associated with Fluviral S/F vaccine (Shire Biologics), 3.8 million doses of which had been distributed. Only 1% of ORS reports were associated with Vaxigrip or Fluzone vaccine (Aventis Pasteur), both of which were also distributed in Canada during the 2000-2001 influenza season (9.8 million total doses) [3, 4] . A retrospective cohort investigation found the highest rates (up to 16%) among vaccinated women aged 40-59 years [5] . Although the case definition was satisfied by the presence of a single qualifying symptom, more than onehalf of affected persons reported multiple oculorespiratory effects [6, 7] . Older persons and those with chronic conditions described more severe and/or prolonged symptoms [6] . More than one-fourth of the reports described symptoms that lasted 148 h. To better reflect these reports, the Canadian National Advisory Committee on Immunization (NACI) updated the case definition for ORS before the 2001-2002 influenza season. The updated case definition specified onset within 24 h after influenza vaccination, with no restriction on duration, and added swallowing difficulty and hoarseness as qualifying respiratory events [3] .
All 3 vaccines distributed in Canada during the 2000-2001 influenza season were inactivated, split-formulation products that included the same 3 virus components. Shire Biologics used a different splitting agent (sodium deoxycholate) than did Aventis Pasteur (Triton X-100). Product-related investigations confirmed complete inactivation of virus and found no contamination [3, 4] . Electron microscopy performed by 3 independent laboratories, however, found that the implicated vaccine contained large aggregates, some comprised of 1500 unsplit virions. Aggregates were practically absent from the 1999 formulation of the implicated vaccine and from the com- The immunologic cause of ORS remains unknown [8, 9] . Hallmark features are suggestive of an allergic response (facial swelling) but also of influenza itself (red eyes, cough, sore throat, and chest discomfort) [10] . Results of skin testing could not predict subsequent risk of ORS recurrence but showed that ORS was not anaphylactic in nature [8] . A high recurrence rate was, nevertheless, seen in affected persons tested with minute quantities of the implicated vaccine [8] . The manufacturer altered the production process to combine Triton X-100 with sodium deoxycholate for splitting the A/Panama strain produced for the 2001-2002 campaign. Before release of the reformulated vaccine, Health Canada required the manufacturer to assess the risk of ORS recurrence in previously affected adults. We describe the results of that trial.
METHODS
Study design. This study was designed as a multicenter, randomized, double-blind, placebo-controlled crossover trial. All participants were to receive vaccine and placebo by random sequence allocation, with administration of each separated by 1 week (minimum separation, 5 days). Participants were enrolled at 4 sites in the provinces of Quebec, Manitoba, Alberta, and British Columbia.
A convenience sample of 150 subjects was sought to identify an ORS recurrence rate that was not !5%. Two safety rules were incorporated into the study design. Experience with the reformulated vaccine was first assessed in a sample of 344 participants who had not previously been affected by ORS and who were participating in a concurrent study that had started earlier [11] . A low rate of occurrence of ORS (р2%) in the interim analysis of that trial allowed initiation of the recurrence study. An early stopping rule was set at a vaccine-attributable ORS recurrence rate of у10%. The study statistician made daily confidential ORS tallies to alert investigators if this safety threshold was exceeded. A data monitoring and safety board was created to assist with key decisions [12] . The ethics boards of all participating centers approved the trial. . The A/Panama strain was split using both Triton X-100 and sodium deoxycholate detergents, whereas the other strains were split using only the latter. Completeness of splitting was confirmed by electron microscopy before lot release. Placebo injection consisted of 0.5 mL of 0.9% saline solution without preservative. Vaccine and placebo appeared indistinguishable.
Participants. Eligible participants were у19 years of age and had experienced ORS following receipt of Fluviral S/F during the 2000-2001 influenza season. Previous onset of ORSqualifying symptoms within 1-2 days after vaccination in 2000-2001 and full resolution of symptoms within 1-2 days after onset were specified as inclusion criteria. Volunteers were excluded from the study if they were allergic to any component of the vaccine, had immune system impairment, were pregnant, or had an active neurologic disorder, bleeding tendency, or ocular or respiratory condition that could hamper ORS recognition. Immunization was delayed in the event of febrile illness (oral temperature, у38ЊC).
Safety assessments. The principal outcome measure was the vaccine-attributable recurrence rate of ORS estimated by the risk difference between vaccine and placebo. Two definitions of ORS were used. The definition specified during the study design reflected the definition that was derived early in 2000 [1, 2] ; this earlier definition restricted ORS duration to р48 h, and we refer to it as "ORS2000." The NACI updated this case definition to remove the restriction on ORS duration for the 2001-2002 influenza season [4] ; we therefore also analyzed data according to this updated case definition, which we refer to as "ORS2001." For both analyses, ORS-defining symptoms included bilateral conjunctival redness, respiratory symptoms (cough, wheeze, chest discomfort, difficulty breathing, difficulty swallowing, hoarseness, and/or sore throat), and facial swelling (eyelid, lip, tongue, and/or other facial swelling).
Participants were observed for 30 min after injection. The safety assessment was based on a combination of participants' daily observations guided by a detailed worksheet, an evening telephone call to participants on the day of the injection, and structured interviews with participants 24 h and 6 days after injection. When participants reported symptoms consistent with ORS during the interview conducted 24 h after injection, another interview at 48 h after injection assessed the duration of illness.
Oral temperature measurements were performed during the first 3 evenings after injection and at any time that fever was suspected. Solicited symptoms included ORS-defining symptoms (as described previously), other ocular symptoms, injection site symptoms, systemic symptoms (including fever, defined as a temperature of у37.7ЊC), gastrointestinal symptoms, and other nonspecific complaints. At each follow-up interview, participants were given the opportunity to describe unsolicited symptoms. A Likert scale for severity was based on the impact of symptoms on regular activities (i.e., no impact, interference, or prevention). Participants were asked to apply this scale to ocular symptoms, breathing or swallowing difficulty, chest discomfort, and overall adverse event(s) experienced by day 6 after injection.
Statistical analysis. A P value of .05 was considered to be statistically significant. The x 2 test was used for categorical variables, and the appropriate parametric test (Student's t test) or nonparametric test (Mann-Whitney U test) was used for continuous variables. Independent effects were assessed by means of logistic regression. Exact binomial distribution was used to calculate 95% CIs.
RESULTS

Disposition of participants. Immunizations began on 13
September 2001. A joint decision was made by investigators and the data monitoring and safety board to halt immunizations on 20 September 2001, the date on which, after careful review of each report, the early stopping rule was found to have been exceeded. When the study was halted, 73 participants had been enrolled, of whom 61 met inclusion and exclusion criteria and had received a first injection, 34 with vaccine ("vaccine group") and 27 with placebo ("placebo group"). All 61 participants completed follow-up interviews; none were given a second injection. Analysis is based on data for these 61 participants.
Baseline characteristics. The vaccine and placebo groups were balanced with respect to age, sex, ethnicity (all were white), and relevant underlying medical conditions ( Table 3 .
Severity indicators of oculorespiratory syndrome symptom (ORS), as defined according to the ORS2001 definition, reported 24 h and 6 days after injection. NOTE. ORS2001-defining symptoms were as follows: onset of bilateral red eyes, respiratory symptoms (cough, difficulty swallowing, difficulty breathing, wheeze, chest discomfort, sore throat, and/or hoarseness), and facial swelling within 24 h after injection [4] .
a Study staff contacted regarding red and itchy eyes. b One subject in the vaccine group sought medical advice between days 2 and 6 after injection regarding muscle aches, joint aches, chills, nausea, and diarrhea.
ticipants had experienced respiratory symptoms, and twothirds had experienced ocular symptoms. Forty-four percent experienced у2 categories of ORS-defining symptoms, which were most often ocular and respiratory. None had facial symptoms alone. Fifteen (24%) had red eyes alone, and 19 (31%) had respiratory symptoms alone. Among the 34 who reported having an ORS symptom from only 1 category (ocular or respiratory), 27 had у1 such symptom (most often cough and chest discomfort or breathing trouble) so that, overall, 89% of participants had experienced multiple ORS-defining symptoms in 2000-2001. ORS recurrence. Of the 61 participants who received an injection, 18 described onset of ORS-defining symptoms within 24 h after the injection, including 15 (44%) of the 34 persons who received vaccine and 3 (11%) of the 27 who received placebo (OR, 4.0; 95% CI, 1.4-37.8; table 2). This provides an estimate of the vaccine-attributable recurrence risk associated with ORS2001 of 33% (95% CI, 10%-53%). The distribution of ORS reports with respect to study center paralleled that of participant enrollment.
Of the 15 vaccine recipients affected by ORS, symptoms resolved within 48 h in 13 and beyond 120 h in 2. Symptoms in all 3 placebo recipients resolved within 48 h after onset. Thus, 13 (38%) of 34 participants who were vaccinated met the ORS2000 case definition that stipulated resolution of symptoms within 48 h after onset, compared with 3 (11%) of 27 placebo recipients (OR, 5.0; 95% CI, 1.1-30.0). The estimated vaccine-attributable recurrence risk of ORS according to the ORS2000 case definition was thus 27% (95% CI, 5%-47%). Because the updated ORS2001 case definition is currently recommended by NACI for purposes of surveillance [4] , further results will be presented for this definition only.
Of the 3 persons who reported having ORS2001-defining symptoms following placebo injection, 1 reported having only bilateral red eyes and 2 reported having only respiratory symptoms (1 described having hoarseness alone and 1 described having cough plus sore throat). A syndrome consisting of у1 ORSdefining symptom was experienced by 11 (32%) of 34 vaccine recipients, compared with 1 (4%) of 27 placebo recipients ( ). Eight (53%) of 15 vaccine recipients experienced P p .01 symptoms (which were most often ocular and respiratory) from у2 categories of ORS2001-defining symptoms. Cough was the most frequent symptom among vaccine recipients (35%), followed by bilateral red eyes (29%), but both of these symptoms were infrequent among placebo recipients (4% vs. 4%; P p and , respectively). The combination of red eyes and .01 P p .02 cough was also reported more often among recipients of vaccine (20%) than among recipients of placebo (0%).
Most symptom recurrences were considered to be mild and easily tolerated (table 3) . One vaccinated participant sought medical advice from study staff within 24 h after injection for red and itchy eyes that interfered with the participant's activities.
Risk factors for ORS2001-defining symptom recurrence among vaccine recipients. Age as a continuous variable was a significant risk factor for ORS2001-defining symptom recurrence among vaccinated participants ( , by the Mann-P p .02 Whitney U test; figure 1) . Participants who experienced recurrence were more likely to be elderly (age, у65 years; P p ). Results of multivariate analysis of vaccinated persons .04 showed that age of у65 years remained a significant predictor of ORS recurrence, independent of underlying chronic condition or sex. The ORS recurrence rate among vaccinated persons was 20% (1 of 5 participants) among those 20-39 years of age, 38% (8 of 21) among those 40-59 years of age, 60% (3 of 5) among those 60-64 years of age, and 100% (3 of 3) among those у65 years of age.
For those who had experienced symptoms from 1, 2, or all 3 categories of ORS symptoms (i.e., ocular, respiratory, and facial) in 2000, 40% (8 of 20 participants), 45% (5 of 11), and 67% (2 of 3) experienced a recurrence in 2001, respectively ( ). Recurrence risk did not vary with respect to self-P p . Vaccinated persons were significantly more likely than were placebo recipients to report injection site symptoms (41% vs. 7%; ; P р .01 table 4). Among those vaccinated, however, persons who experienced recurrence of ORS2001-defining symptoms were less likely to report local symptoms-in particular, pain-than were those who did not report recurrence of such symptoms.
DISCUSSION
This randomized, double-blind, placebo-controlled trial documents a vaccine-attributable recurrence rate of ORS2001-defining symptoms of 1 in 3 vaccinated persons (33%); when illness duration is limited to 48 h, this rate is ∼1 in 4 vaccinated persons (27%). Clinical reviews of ORS have supported preferential use of the case definition without restriction on duration (i.e., ORS2001); we, therefore, confine our subsequent discussions to this definition [6, 7] The absolute recurrence rate for ORS2001-defining symptoms among vaccinated persons in our trial (44%; 95% CI, 28%-62%) is similar to the recurrence estimate found in a previous skin test evaluation that used minute quantities of the implicated vaccine manufactured for the 2000-2001 influenza season (45%; 95% CI, 30%-70%), as well as results from a survey conducted in Quebec of persons who received the reformulated vaccine during 2001-2002 (30%; 95% CI, 18%-42%) [8, 13] . Our estimates of the absolute recurrence rate are several-fold higher than the absolute occurrence rate found in a concurrent clinical trial involving previously unaffected persons that used the same vaccine and methodological design (6%; 95% CI, 4%-8%) [11] . Results suggest that a subset of the population may retain heightened sensitivity to the trigger associated with ORS. Whether this heightened sensitivity is primarily host-or vaccine-related and whether it will persist is NOTE. ORS2001-defining symptoms were as follows: onset of bilateral red eyes, respiratory symptoms (cough, difficulty swallowing, difficulty breathing, wheeze, chest discomfort, sore throat, and/or hoarseness), and facial swelling within 24 h after injection [4] .
a P values compare data for those who reported with data for those who did not report ORS2001 symptoms. b P values compare data for vaccine recipients with data for placebo recipients. unknown, but there is evidence, which is being further evaluated in follow-up investigations [13] , that ORS can also be induced by other manufacturers' products.
Previously affected persons who experienced a recurrence of ORS in this clinical trial differed from previously unaffected persons in the nature of their ORS experience. In the trial of previously unaffected persons, ORS involved a single eligible symptom in 67% of cases, whereas, in our trial, recurrent ORS episodes involved у2 symptoms in 73% (11 of 15 cases) [11] . Such a presentation is more in agreement with reports to the passive surveillance system during 2000-2001 [4, 6, 7] . Cough and red eyes emerged as the dominant presentations among participants who experienced a recurrence of ORS in this trial. Other ORS symptoms did not occur more frequently following vaccine administration, although the study was neither originally nor ultimately powered to detect such individual symptom differences.
Although one-half of the participants had experienced breathing difficulty or chest discomfort during their original ORS experience in 2000-2001, few participants (!20%) in the current trial reported having these disturbing respiratory symptoms as part of their ORS recurrence. None had symptoms that prevented regular activities, and, despite 24-h access, only 1 person contacted study staff because of ORS during the 6-day postinjection period. Nearly 90% experienced full resolution within 48 h after onset. These findings should be reassuring to previously affected persons in terms of the low risk of clinically significant recurrence and the reduced severity relative to that associated with ORS in 2000-2001.
Whereas middle-aged persons experienced the highest ORS rates during the 2000-2001 influenza vaccination campaign [5] , the recurrence rate in this trial was highest among elderly persons. Other vaccine-associated symptoms did not show the same age-related effect. The reason for the shift in the age distribution of ORS is unclear; it was not related to an increase in the number of chronic conditions associated with advanced age. The number of persons included within each age subcategory is small, and estimates are therefore unstable and should not be considered conclusive. It may be that the residual risk of mild ORS recurrence is more perceptible when experienced by individuals who are already frail. In 2000-2001, elderly persons described symptoms in more severe terms in one review [6] . ORS symptoms have not been detected in other investigations of the safety of influenza vaccine in elderly individuals, but these studies did not specifically inquire about these symptoms associated with the vaccine within 24 h after injection [14] [15] [16] . This study found a higher rate of systemic and injection site complaints following vaccination, compared with that following placebo administration. It may be that vaccinated participants formed an opinion regarding which injection they received on this basis and then searched harder for vaccineassociated ORS symptoms and reported them more often. Although this bias cannot be ruled out, it is unlikely to have influenced the estimate of ORS recurrence. Persons reporting ORS were, in fact, less likely to note injection site effects than those who did not experience ORS.
In summary, a significant vaccine-attributable recurrence rate for ORS was found in this rigorously conducted trial. In accordance with safety guidelines, the trial was halted early. Because of the reduced number of participants, estimates must be qualified by wide CIs spanning from !10% to 150%. One may question whether such mild symptoms would have been recalled if follow-up had not been so intense and whether such symptoms have any programmatic implications. This trial is among the first to systematically query for onset of adverse events within 24 h after influenza vaccination. Far lower estimates of the recurrence rate (range, 5%-10%) have been found in community-based telephone surveys, in which 1100 previously affected persons were interviewed 6 months after revaccination [17] (J.L. Grenier, personal communication). Participants in the current trial were not asked directly whether, on the basis of their experience, they would receive the vaccine again, and this consideration was not incorporated into the safety guidelines. In a subsequent survey, two-thirds of those who experienced symptom recurrence said they would still be revaccinated [17] .
Previously affected individuals should be informed of the recurrence rate for ORS, but they should also be informed that recurrent episodes are mild and easily tolerated. This risk should be balanced against the risks of influenza itself, particularly among elderly individuals or those with chronic conditions, as well as against the proven benefits of vaccination [10, 18, 19] . Because even mild adverse events can be significant determinants of risk-benefit perception and willingness to be revaccinated, the cause of ORS should be addressed.
